Compass Pathfinder Limited

Cyclacel Limited

Verona Pharma Plc

Alexion Pharmaceuticals, Inc.

Activesite Pharmaceuticals, Inc.

Rezolute, Inc.

Crt Pioneer Fund LP

Kalvista Pharmaceuticals Limited

Compass Pathways Limited

Julian Scott Northen

Derek John Londesbrough

David E Nichols

Christopher Brown

Gillian Moore

Hemant Kashinath Patil

Ekaterina Malievskaia

George Goldsmith

Manon Cecile Elisabeth Veraart

Lars Christian Wilde

John Mykytiuk

Philippe Fernandes

Tobias Patrick Whelan

Hans Åke Eriksson

Stephen Wright

Benjamin Mark Skead

Megan Croal

Amanda Tan Shuxiang

Anaïs Soula

Aslihan Selimbeyoglu

Nathan Poulsen

Drummond E-Wen Joe McCulloch

Lindsey Marwood

Shaun Hurley

Molly Tabitha Hickey

Jonathan Charles Christian Atherton

Laurie Emma Medhurst

Anjali Pandey

Sukanto Sinha

Sami Karaborni

Tamie Chilcote

Peter Lionel Spargo

Ying Chen

Christopher Peter Worrall

Edward James French

Hans Ake Eriksson

Jamie Marshall

Yuelie Lu

Gus Kodersha

Bertrand M C Plouvier

Robert Westwood

Michael J A Walker

Philippe Fernades

Chris Atherton

Bertrand M Plouvier

Michael J Walker

Ben Skead

This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.

Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.

Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin

Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat neurocognitive disorders (e.g., Alzheimer's disease, Parkinson's disease), ADHD, Epilepsy, Autism, Sleep-wake disorders, Chronic pain, Inflammatory Disorders, IBD, Stroke, ALS, and/or Multiple Sclerosis.

Methods of treating neurocognitive disorders, chronic pain and reducing inflammation

Pure crystalline forms of 1-benzyl-N-(4-carbamimidoylbenzyl)-1H-pyrazole-4-carboxamide acetate, and an amorphous form, pharmaceutical compositions thereof, and methods for making the same, are disclosed.

Crystalline forms of plasma kallikrein inhibitors

Ditosylate salts of N2-(2-ethoxy-4-(4-methyl-4H-1,2,4-triazol-3-yl)phenyl)-6-methyl-N8-neopentylpyrido[3,4-d]pyrimidine-2,8-diamine, and crystalline forms thereof; processes for the preparation of the new salt forms; and their use as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer.

Salt form

Diphosphate salts of N2-(2-ethoxy-4-(4-methyl-4H-1,2,4-triazol-3-yl)phenyl)-6-methyl-N8-neopentylpyrido[3,4-d]pyrimidine-2,8-diamine, and crystalline forms thereof, processes for the preparation of the new salt forms; and their use as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer.

Forms of cerdulatinib and salts or co-crystals thereof were prepared and characterized in the solid state. Also provided are processes of manufacture and methods of using the forms cerdulatinib and salts or co-crystals thereof.

Solid forms of Cerdulatinib

Growing community of inventors

South Shields, United Kingdom

Julian Scott Northen